InvestorsHub Logo
Followers 0
Posts 6541
Boards Moderated 0
Alias Born 05/08/2014

Re: None

Thursday, 12/15/2016 1:09:12 AM

Thursday, December 15, 2016 1:09:12 AM

Post# of 561
WOW!!!! Read closely!!! Pursuant to the Agreement, Wyeth has granted the Company an exclusive license to Wyeth’s proprietary rights that apply to Factor VIIa variants, CB 813a and CB 813d, to research, DEVELOP, MANUFACTURE and COMMERCIALIZE the Products. Wyeth has also transferred and will transfer to the Company documentation related to the development, manufacturing and testing of the Products, including the Investigational New Drug application.

$CBIO extremely undervalued

Trade at your own risk.

867$$$

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CBIO News